rss
Br J Ophthalmol 2008;92:351-355 doi:10.1136/bjo.2007.123513
  • Original Article

Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion

  1. T C Kreutzer1,
  2. C S Alge1,
  3. A H Wolf1,
  4. D Kook1,
  5. J Burger1,
  6. R Strauss1,
  7. C Kunze2,
  8. C Haritoglou1,
  9. A Kampik1,
  10. S Priglinger1
  1. 1
    Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
  2. 2
    Department of Ophthalmology, Medical University, Innsbruck, Austria
  1. Dr S G Priglinger, Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Mathildenstr 8, 80336 Munich, Germany; siegfried.priglinger{at}med.uni-muenchen.de
  • Accepted 27 November 2007
  • Published Online First 22 January 2008

Abstract

Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion.

Methods: A prospective, non-comparative, consecutive, interventional case series of 34 patients. Patients received repeated intravitreal injections of 1.25 mg bevacizumab. Main outcome measures were VA (Snellen charts and ETDRS) and retinal thickness (optical coherence tomography measurements) in a follow-up period of 6 months.

Results: Patients presented at a mean age of 69 years (range 44–86). Mean duration of symptoms was 40 weeks (range 1–300). Mean (SD) VA at baseline was 0.79 (0.39) logMAR, improving to 0.51 (0.34) logMAR at 6 months (p = 0.009). Mean number of letters on the ETDRS chart at baseline was 45.3 (19.0), improving to 60.6 (19.9) at 6 months (p = 0.003). Mean (SD) retinal thickness at baseline was 474 (120) μm, declining to 316 (41) μm at 6 months.

Conclusion: Intravitreal injection of 1.25 mg bevacizumb appears to be an effective treatment option for branch retinal vein occlusion.

Footnotes

  • Part of this work has been presented at the 6th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT), Berlin, 2006.

  • Competing interests: None declared.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2007.123513v1
    2. 92/3/351 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.